Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) insider Gregory Russotti sold 5,000 shares of the stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $3.12, for a total transaction of $15,600.00. Following the sale, the insider now owns 292,319 shares in the company, valued at $912,035.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Gregory Russotti also recently made the following trade(s):
- On Monday, April 22nd, Gregory Russotti sold 5,000 shares of Century Therapeutics stock. The shares were sold at an average price of $3.10, for a total transaction of $15,500.00.
Century Therapeutics Stock Up 6.3 %
NASDAQ IPSC opened at $3.37 on Wednesday. Century Therapeutics, Inc. has a 52 week low of $1.28 and a 52 week high of $5.51. The business has a 50 day moving average price of $3.90 and a 200-day moving average price of $3.22. The company has a market cap of $218.44 million, a price-to-earnings ratio of -1.47 and a beta of 1.44.
Hedge Funds Weigh In On Century Therapeutics
Several large investors have recently added to or reduced their stakes in the business. Abel Hall LLC bought a new stake in shares of Century Therapeutics in the 4th quarter worth $33,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Century Therapeutics during the first quarter worth about $47,000. Federated Hermes Inc. grew its position in Century Therapeutics by 0.4% in the 4th quarter. Federated Hermes Inc. now owns 618,482 shares of the company’s stock worth $2,053,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Avidity Partners Management LP increased its stake in Century Therapeutics by 23.4% in the 4th quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock valued at $4,499,000 after buying an additional 256,500 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on IPSC shares. Canaccord Genuity Group lifted their price objective on Century Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Century Therapeutics in a report on Friday, March 15th. Finally, Piper Sandler restated an “overweight” rating and set a $9.00 price target (down from $10.00) on shares of Century Therapeutics in a report on Friday, April 12th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $13.60.
View Our Latest Research Report on IPSC
About Century Therapeutics
Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.
Featured Stories
- Five stocks we like better than Century Therapeutics
- What is the Australian Securities Exchange (ASX)
- Garmin Navigates to New Highs Driven By Wearables Trend
- What Are Dividends? Buy the Best Dividend Stocks
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- How to Invest in Small Cap StocksĀ
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.